HighTide

HighTide Therapeutics Appoints Myleen Leoncavallo as SVP Regulatory Affairs and Quality Assurance

Retrieved on: 
Thursday, March 31, 2022
Biotechnology, General Health, Pharmaceutical, Health, Drug development, BioMarin Pharmaceutical, Therapy, University, Primary biliary cholangitis, Degenerative disease, Master of Science, Institute of Liver and Biliary Sciences, Regulatory affairs, Quality assurance, Cholestasis, Primary sclerosing cholangitis, Pregnancy, Biliary atresia, Medicinal chemistry, University of California, San Diego, HighTide, Cholestatic pruritus, Senior, Cell biology, T2DM, Alagille syndrome, Clinical trial, Hypertriglyceridemia, Patient, Pharmaceutical industry, Biochemistry, Science, Spiroplasma mirum

HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.
  • Mrs. Leoncavallo will report to Dr. Leigh MacConell, Chief Development Officer of HighTide.
  • We are very pleased to welcome Myleen to HighTide, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.
  • Prior to Mirum, Mrs. Leoncavallo served in several senior regulatory affairs roles, including positions at Ultragenyx Pharmaceuticals and BioMarin Pharmaceuticals, biopharmaceutical companies focused on rare diseases.

HighTide Therapeutics Announces End-of-Phase 2 Meeting with FDA and Agreement to Proceed to Phase 3 for HTD1801 for the Treatment of PSC

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Roy Taylor (scientist), Lists of diseases, Primary biliary cholangitis, Serum, ALP, Alkaline phosphatase, Therapy, Review, T2DM, Food, Adult, Degenerative disease, Comment, Fatty liver disease, FDA, Patient, NAFLD, NASH, HighTide, PSC, Primary sclerosing cholangitis, Food and Drug Administration, Hypertriglyceridemia, Pharmaceutical industry

As previously announced, the company completed a Phase 2 study of HTD1801 in patients with PSC.

Key Points: 
  • As previously announced, the company completed a Phase 2 study of HTD1801 in patients with PSC.
  • This dose-ranging, double-blind, placebo-controlled Phase 2 clinical trial evaluated the treatment effects of HTD1801 in 55 adult patients with PSC conducted at over 20 clinical sites in the U.S. and Canada.
  • Serum levels of gamma-glutamyl transferase, alanine aminotransferase, and aspartate aminotransferase also were reduced with both doses of HTD1801 compared with placebo.
  • We would like to acknowledge the helpful guidance that FDA has provided, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.

HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology

Retrieved on: 
Thursday, January 6, 2022
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, NASH, Therapy, University, Fatty liver disease, Chronic liver disease, Roy Taylor (scientist), Lists of diseases, Patient, Primary biliary cholangitis, IND, T2DM, Chen Jin, Pharmacology, Buffalo, NAFLD, PSC, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Degenerative disease, SVP, Institute of Liver and Biliary Sciences, Drug, Clinical pharmacology, Amgen, State, Primary sclerosing cholangitis, HighTide, State university system, PBC, NDA, Pharmaceutical industry, Novartis

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.

Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.
  • Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development.
  • Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio, renal, metabolic, and liver diseases.
  • We are very pleased to welcome Jin to the HighTide team, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.

Alpine IQ Continues Growth Trajectory with High Tide Inc. Partnership

Retrieved on: 
Thursday, December 2, 2021
Aurora, CEO, Industry, Company, Partnership, Alpine, Data analysis, CBD, Solution, Business, High Tide, GLOBE, HighTide, Tilray, FSE, Retail

BROOMFIELD, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Alpine IQ, the leading data and marketing solutions provider for cannabis retailers, today announced its partnership with High Tide Inc. (TSXV: HITI) (Nasdaq: HITI) (FSE: 2LYA), North Americas first Cannabis Discount Club retailer.

Key Points: 
  • BROOMFIELD, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Alpine IQ, the leading data and marketing solutions provider for cannabis retailers, today announced its partnership with High Tide Inc. (TSXV: HITI) (Nasdaq: HITI) (FSE: 2LYA), North Americas first Cannabis Discount Club retailer.
  • High Tide tapped Alpine IQ to power its loyalty program, leveraging the companys robust suite of tools to engage with customers, drive increased satisfaction, and ultimately, repeat visits.
  • "HighTide continues to innovate with the first ever discount member card across over 100 stores, said Nicholas Paschal, co-founder and CEO of Alpine IQ.
  • Alpine IQ empowers the legal cannabis industry by providing customer-focused technology to help retailers of all sizes resolve growth challenges and generate revenue.

HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021

Retrieved on: 
Thursday, October 28, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibrosis, Program, UDCA, Astrophysics Strategic Mission Concept Studies, Orphan drug, Weight loss, Central nervous system disease, 2021 Essex County Council election, AASLD, Primary sclerosing cholangitis, Fatty liver disease, Ursodeoxycholic acid, PBC, US, Association, CNS, NAFLD, Fast Track, T2DM, Patient, Liver injury, Roy Taylor (scientist), ALT, Cholestasis, Liver disease, American Association for the Study of Liver Diseases, HighTide, Chronic liver disease, PSC, American Association, Therapy, NASH, Diabetes, Doctor of Philosophy, Berberine, Primary biliary cholangitis, Pharmaceutical industry, Medical imaging, Dietary supplement, HTD1801, HighTide Therapeutics, HTD1801, HIGHTIDE THERAPEUTICS

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
  • The data will be presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2021, being held virtually November 12-15, 2021.
  • We are excited to present new HTD1801 clinical data in both PSC and NASH, said Liping Liu, PhD, Founder and Chief Executive Officer of HighTide.
  • HTD1801 has received Fast Track designation from the US FDA for both PSC and NASH, as well as Orphan Drug designation for PSC.

HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients

Retrieved on: 
Tuesday, September 21, 2021
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ursodeoxycholic acid, Therapy, HighTide, Prevalence, Weight loss, Type 2 diabetes, Fatty liver disease, Liver disease, Berberine, PSC, Inflammation, T2DM, Liver injury, Biliary reflux, Diabetes, Fast Track, Patient, MD, NAFLD, Nausea, Liver cancer, Glycated hemoglobin, NASH, CEO, Magnetic resonance imaging, Degenerative disease, Nature Communications, Disease, Hepatitis, CTCAE, Liver, Lists of diseases, BID, Safety, Fibrosis, Cirrhosis, Orphan drug, US, Diarrhea, Pharmaceutical industry, Medical imaging, NASH, HTD1801, HighTide Therapeutics, NASH, HTD1801, HIGHTIDE THERAPEUTICS

The totality of the data support our expectation that HTD1801 could benefit a significant number of patients with NASH and diabetes, said Liping Liu, CEO of HighTide.

Key Points: 
  • The totality of the data support our expectation that HTD1801 could benefit a significant number of patients with NASH and diabetes, said Liping Liu, CEO of HighTide.
  • NASH is often a liver manifestation of a systemic metabolic disorder, said Stephen Harrison, MD, medical director of Pinnacle Clinical Research and lead author.
  • This trial in patients with presumed NASH and T2DM demonstrated HTD1801s potential to treat NASH while also addressing the underlying metabolic driver of the disease.
  • The study results show that HTD1801 is relatively well tolerated and merits further development as a treatment for NASH with diabetes.

HighTide Therapeutics Appoints Dr. Leigh MacConell as Chief Development Officer

Retrieved on: 
Monday, February 1, 2021
Health, Diabetes, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Intercept Pharmaceuticals, HighTide, Obeticholic acid, Health care, Medical specialties, Medicine

HighTide Therapeutics Inc. (HighTide), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as Chief Development Officer.

Key Points: 
  • HighTide Therapeutics Inc. (HighTide), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as Chief Development Officer.
  • Most recently Dr. MacConell served as Senior Vice President, Clinical Development at Intercept Pharmaceuticals where she provided strategic leadership for the global clinical development of obeticholic acid (OCA).
  • Reporting to Liping Liu, Ph.D., founder and CEO of HighTide, Dr. MacConell will lead the companys global clinical development, regulatory and quality functions, and will focus on driving the advancement of the companys pipeline.
  • This year represents a significant step for HighTide as we transition to a late-stage clinical development company, said Dr. Liu.